Bayer lifts 2026 profit outlook after strong pharma sales
In short
Bayer raised its 2026 profit outlook after its pharmaceuticals business had stronger-than-expected third-quarter sales. It also lowered its debt forecast.
The update points to better growth and a stronger balance sheet, but the report does not give the new targets or the sales numbers.
What the reporting says
Bayer raised its 2026 profit outlook after its pharmaceuticals division delivered stronger-than-expected third-quarter sales. The group also lowered its debt forecast, according to an Economic Times Markets summary, suggesting improving financial momentum. The available reporting does not state the revised targets or the size of the sales beat.
Why it matters
Bayer lifted its 2026 profit outlook after stronger-than-expected third-quarter sales in its pharmaceuticals division, and it also lowered its debt forecast. The move suggests better growth momentum and a stronger financial position, but the available summary does not provide the revised guidance figures or the exact sales outperformance.